A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, according to a recently published review.

Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF ... which has demonstrated sustained ...

The team revealed distinct phases where waves of immune responses give way to lung fibrosis—scarring of ... damage from COVID ...